Entity

Time filter

Source Type


Lin J.,Shanghai First Peoples Hospital
Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences | Year: 2013

To evaluate the efficacy and safety of combining reduction plating with reamed intramedullary nailing for segmental fractures of proximal-middle tibia. From June 2007 to October 2011, 31 patients with segmental fractures of proximal-middle tibia were admitted. There were 18 males and 13 females, with an average age of 45.2 years (range: 23-77 years), of whom, 9 were Gustilo I type open fractures and 22 were close fractures. All the patients were treated with assisting plate combined with reamed intramedullary nailing. The operation was performed averagely 35 h (range: 16-72 h) after injury. During the post-operation follow-up radiographic evaluation, the range of knee joint, and Johner-Wruhs scores were measured. All the patients were followed-up for 18.5 months (range: 17-24 months). No wound infection or osteofascial compartment syndrome happened. All the fractures healed after 5.1 months (range: 4-6 months). The proximal and distal fracture sites healed simultaneously. No malunion was found. In the last follow-up, the mean range of knee joint was 9°-0°-127°, and according to Johner-Wruhs scores, 19 were excellent, 10 good, and 2 fair. Assisting plate with reamed intramedullary nailing is a safe and effective alternative choice for segmental fractures of proximal-middle tibia, which can ease the difficulty of the procedure, improve the quantity of reduction and enhance the stability of the hardware. Source


To investigate the isolation and expansion of mesenchymal stem cells (MSCS) from human umbilical cord Wharton's jelly and their biological identities, and explore the possibility of inducing human umbilical cord-derived MSCS to differentiate into chondrogenic and osteogenic cells. The hUCMSCs were isolated form human umbilical cord by tissue adherence and digested with collagenase NB4, dispase II and hyaluronidase. The morphology, proliferation and immunophenotype of the 3rd passage cells were analyzed, and then the chondrogenic and osteogenic differentiation was tested and evaluated by specific staining methods.cells were induced to chondrogenic and osteogenic differentiation in vitro. The isolation of hUCMSCs by digestion with collagenase NB4, dispase II and hyaluronidase was efficient. After seeded for 24 hours, the adherent cells showed spindle shape and fibroblast cell-like shape and the size of hUCMSCs was homogeneous. Flow cytometry analysis revealed that the hUCMSCs were positive for CD44, CD105, CD90, CD73, but were negative for CD45, CD34, CD14, CD19 and HLA-DR. These cells could be induced to differentiate into chondrogenic and osteogenic cells under proper inducing conditions. The hUCMSCs retained the appearance and phenotype even after being expanded more than 40 passages in vitro. The human MSCs could be isolated from human umbilical cord Wharton's jelly, and it was easy to propagate these MSCs. An in vitro method for isolation and purification of hUCMSCs from human umbilical cord has been established. The cultured cells were composed of only undifferentiated cells and their biological properties were stable. The hUCMSCs are expected to be a new type of stem cells of tissue engineering. Source


Li X.,Peking University | Xu G.,Fudan University | Wang Y.,Xijing University | Xu X.,Shanghai First Peoples Hospital | And 8 more authors.
Ophthalmology | Year: 2014

Purpose To assess the safety and efficacy of multiple injections of 0.5 and 2.0 mg conbercept using variable dosing regimens in patients with neovascular age-related macular degeneration (AMD). Design Randomized, double-masked, multicenter, controlled-dose, and interval-ranging phase 2 clinical trial divided into a 3-month loading phase followed by a maintenance phase. Participants Patients with choroidal neovascularization secondary to AMD with lesion sizes of 12 disc areas or less and a best-corrected visual acuity (BCVA) letter score of between 73 and 24 were enrolled. Methods Patients were randomized 1:1 to receive either 0.5 or 2.0 mg intravitreal conbercept for 3 consecutive monthly does. After the third dose, each group was reassigned randomly again to monthly (Q1M group) or as-needed (pro re nata [PRN] group) treatment without changing the drug assignment. Main Outcome Measures The primary end point was the mean change in BCVA from baseline to month 3, with secondary end points being the mean change in BCVA, mean change in central retinal thickness (CRT), and safety at month 12. Results We enrolled 122 patients. At the primary end point at month 3, mean improvements in BCVA from baseline in the 0.5- and 2.0-mg groups were 8.97 and 10.43 letters, respectively. At month 12, mean improvements in BCVA from baseline were 14.31, 9.31, 12.42, and 15.43 letters for the 0.5-mg PRN, 0.5-mg Q1M, 2.0-mg PRN, and 2.0-mg Q1M regimens, respectively. At month 12, mean reductions in CRT in the 4 regimens were 119.8, 129.7, 152.1, and 170.8 μm, respectively. There were no significant differences for the pairwise comparisons between all study groups. The difference in the number of injections between the 2 PRN groups was not statistically significant. Treatment with conbercept generally was safe and well tolerated. Conclusions The significant gains in BCVA at 3 months were the same or better at 12 months in all conbercept dosing groups of neovascular AMD patients. During the 12 months, repeated intravitreal injections of conbercept were well tolerated in these patients. Future clinical trials are required to confirm its long-term efficacy and safety. © 2014 by the American Academy of Ophthalmology. Source


Patent
Shanghai First Peoples Hospital | Date: 2012-10-29

Provided is a polypeptide having angiogenesis inhibiting activity. The polypeptide is derived from Placenta Growth Factor-1. Also provided are a derivative polypeptide of the polypeptide, a preparation method for polypeptide, and a pharmaceutical composition containing the polypeptide.


Patent
Shanghai First Peoples Hospital | Date: 2011-07-01

Provided is a polypeptide having angiogenesis inhibiting activity. The polypeptide is derived from Placenta Growth Factor-1. Also provided are a derivative polypeptide of the polypeptide, a preparation method for polypeptide, and a pharmaceutical composition containing the polypeptide.

Discover hidden collaborations